Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.

Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN.

Cancer. 2010 Apr 15;116(8):1938-46. doi: 10.1002/cncr.24982.

2.

Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis.

Wang P, Kang D, Cao W, Wang Y, Liu Z.

Diabetes Metab Res Rev. 2012 Feb;28(2):109-22. doi: 10.1002/dmrr.1291. Review.

PMID:
21898753
3.

Increased international normalized ratio level in hepatocellular carcinoma patients with diabetes mellitus.

Zhang H, Gao C, Fang L, Yao SK.

World J Gastroenterol. 2013 Apr 21;19(15):2395-403. doi: 10.3748/wjg.v19.i15.2395.

4.

Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.

Donadon V, Balbi M, Casarin P, Vario A, Alberti A.

World J Gastroenterol. 2008 Oct 7;14(37):5695-700.

5.

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.

Donadon V, Balbi M, Mas MD, Casarin P, Zanette G.

Liver Int. 2010 May;30(5):750-8. doi: 10.1111/j.1478-3231.2010.02223.x. Epub 2010 Mar 12.

PMID:
20331505
6.

Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.

Singh S, Singh PP, Singh AG, Murad MH, Sanchez W.

Am J Gastroenterol. 2013 Jun;108(6):881-91; quiz 892. doi: 10.1038/ajg.2013.5. Epub 2013 Feb 5. Review.

PMID:
23381014
7.

Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort.

Schlesinger S, Aleksandrova K, Pischon T, Jenab M, Fedirko V, Trepo E, Overvad K, Roswall N, Tjønneland A, Boutron-Ruault MC, Fagherazzi G, Racine A, Kaaks R, Grote VA, Boeing H, Trichopoulou A, Pantzalis M, Kritikou M, Mattiello A, Sieri S, Sacerdote C, Palli D, Tumino R, Peeters PH, Bueno-de-Mesquita HB, Weiderpass E, Quirós JR, Zamora-Ros R, Sánchez MJ, Arriola L, Ardanaz E, Tormo MJ, Nilsson P, Lindkvist B, Sund M, Rolandsson O, Khaw KT, Wareham N, Travis RC, Riboli E, Nöthlings U.

Ann Oncol. 2013 Sep;24(9):2449-55. doi: 10.1093/annonc/mdt204. Epub 2013 May 29.

8.

Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis C patients in China.

Li X, Xu H, Gao Y, Pan M, Wang L, Gao P.

Medicine (Baltimore). 2017 Mar;96(13):e6508. doi: 10.1097/MD.0000000000006508.

9.

The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma.

Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C, Serraino D, Franceschi S, Talamini R.

Ann Oncol. 2009 Feb;20(2):353-7. doi: 10.1093/annonc/mdn565. Epub 2008 Aug 22.

PMID:
18723550
10.

ABO blood group and the risk of hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B.

Li Q, Yu CH, Yu JH, Liu L, Xie SS, Li WW, Yang X, Fan WB, Gai ZT, Chen SJ, Kato N.

PLoS One. 2012;7(1):e29928. doi: 10.1371/journal.pone.0029928. Epub 2012 Jan 3.

11.
12.

Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease.

Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G, Miranda C.

World J Gastroenterol. 2009 May 28;15(20):2506-11.

13.

Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.

Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC.

Am J Gastroenterol. 2012 Jan;107(1):46-52. doi: 10.1038/ajg.2011.384. Epub 2011 Nov 15.

PMID:
22085817
14.

Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases.

Bosetti C, Franchi M, Nicotra F, Asciutto R, Merlino L, La Vecchia C, Corrao G.

Pharmacoepidemiol Drug Saf. 2015 Jul;24(7):771-8. doi: 10.1002/pds.3801. Epub 2015 May 27.

PMID:
26013675
15.

Type 2 diabetes and hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B.

Li Q, Li WW, Yang X, Fan WB, Yu JH, Xie SS, Liu L, Ma LX, Chen SJ, Kato N.

Int J Cancer. 2012 Sep 1;131(5):1197-202. doi: 10.1002/ijc.27337. Epub 2011 Dec 21.

16.

Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus.

Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, de Knegt RJ, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL.

Hepatology. 2008 Jun;47(6):1856-62. doi: 10.1002/hep.22251.

PMID:
18506898
17.

The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies.

Yang WS, Va P, Bray F, Gao S, Gao J, Li HL, Xiang YB.

PLoS One. 2011;6(12):e27326. doi: 10.1371/journal.pone.0027326. Epub 2011 Dec 21.

19.

Diabetes is not an independent risk factor for hepatocellular carcinoma.

Tseng CH.

Diabetes Metab Res Rev. 2013 Oct;29(7):515-24. doi: 10.1002/dmrr.2422.

PMID:
23658071
20.

Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans.

El-Serag HB, Kramer J, Duan Z, Kanwal F.

Am J Gastroenterol. 2014 Sep;109(9):1427-35. doi: 10.1038/ajg.2014.214. Epub 2014 Jul 29.

PMID:
25070058

Supplemental Content

Support Center